Requip and Sutent drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Requip (ropinirole hydrochloride) and Sutent (sunitinib malate). Common drug interactions include cranial nerve disorder among females and fatigue among males.

The phase IV clinical study analyzes what interactions people have when they take Requip and Sutent. It is created by eHealthMe based on reports of 45 people who take the same drugs from the FDA, and is updated regularly.

What is Requip?

Requip has active ingredients of ropinirole hydrochloride. It is often used in restless leg syndrome. eHealthMe is studying from 22,950 Requip users. Check the latest studies of Requip.

What is Sutent?

Sutent has active ingredients of sunitinib malate. It is often used in renal cell carcinoma. eHealthMe is studying from 44,554 Sutent users. Check the latest studies of Sutent.

On Jul, 31, 2026

45 people who take Requip and Sutent together, and have interactions are studied.

What are the common drug interactions of Requip and Sutent, by gender? *:

female:

Cranial nerve disorder (impaired functioning of one of the twelve cranial nerves)
Ear infection
Eyelid ptosis (falling of the upper or lower eyelid)
Gastritis (inflammation of stomach)
Headache (pain in head)
Hyperglycaemia (high blood sugar)
Hypertension (high blood pressure)
Mastication disorder (disease of chewing food)
Meningioma malignant (cancerous tumour of membranes that cover the brain and spinal cord just inside the skull)
Mucosal inflammation (infection of mucous membrane)

male:

Fatigue (feeling of tiredness)
Diarrhoea
Dry skin
Foreign body sensation in eyes (feeling of something in eye)
Renal impairment (severely reduced kidney function)
Upper gastrointestinal haemorrhage (upper gastrointestinal bleeding)
Stomatitis (inflammation of mucous membrane of mouth)
Decreased appetite
Arthralgia (joint pain)
Disease progression

What are the common drug interactions of Requip and Sutent, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Seizure (abnormal excessive or synchronous neuronal activity in the brain)

50-59:

Abdominal pain
Blood creatinine increased
Blood glucose increased
Blood pressure increased
Blood urine present
Decreased appetite
Diarrhoea
Dysgeusia (disorder of the sense of taste)
Dyspepsia (indigestion)
Fatigue (feeling of tiredness)

60+:

Fatigue (feeling of tiredness)
Nausea (feeling of having an urge to vomit)
Disease progression
Skin exfoliation (removal of the oldest dead skin cells)
Asthenia (weakness)
Pain in extremity
Weight decreased
Decreased appetite
Hyperhidrosis (abnormally increased sweating)
Oropharyngeal pain

What are the existing conditions these people have? *

Constipation: 10 people, 22.22%
Pancreatic Carcinoma (pancreatic cancer): 9 people, 20.00%
Pain: 9 people, 20.00%
Hiccups (an involuntary spasm of the diaphragm and respiratory organs, with a sudden closure of the glottis and a sound like a cough): 9 people, 20.00%
Thyroid Cancer Metastatic (thyroid cancer spreads to other part): 5 people, 11.11%
Thrombosis (formation of a blood clot inside a blood vessel): 4 people, 8.89%
Renal Cancer Stage Iv (the tumour has spread to areas beyond gerota's fascia and extends into the adrenal gland on the same side of the body as the tumour, possibly to lymph nodes, but not to other parts of the body): 4 people, 8.89%
Renal Cancer Metastatic (cancer of kidney spreads to other part): 3 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Requip and Sutent?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously